Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
50.70
+0.28 (0.56%)
Jun 17, 2025, 4:00 PM - Market closed
Mirum Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Revenue | 379.25 | 336.89 | 186.37 | 77.06 | 19.14 | - | Upgrade
|
Revenue Growth (YoY) | 69.31% | 80.76% | 141.85% | 302.67% | - | - | Upgrade
|
Cost of Revenue | 86.83 | 81.64 | 47.04 | 12.37 | 1.9 | - | Upgrade
|
Gross Profit | 292.42 | 255.25 | 139.34 | 64.69 | 17.24 | - | Upgrade
|
Selling, General & Admin | 214.29 | 202.22 | 145.88 | 89.07 | 59.22 | 22.69 | Upgrade
|
Research & Development | 154.45 | 140.63 | 102.61 | 106.84 | 131.43 | 81.61 | Upgrade
|
Operating Expenses | 368.74 | 342.85 | 248.49 | 195.91 | 190.65 | 104.3 | Upgrade
|
Operating Income | -76.32 | -87.61 | -109.15 | -131.22 | -173.41 | -104.3 | Upgrade
|
Interest Expense | -14.33 | -14.31 | -15.11 | -15.98 | -17.59 | -0.34 | Upgrade
|
Interest & Investment Income | 13.18 | 13.79 | 13.74 | 3.86 | 0.37 | 1.56 | Upgrade
|
Currency Exchange Gain (Loss) | 0.2 | 1.2 | 1.8 | - | - | - | Upgrade
|
Other Non Operating Income (Expenses) | 1.36 | 0.01 | -4.62 | 1.27 | 106.69 | -0.19 | Upgrade
|
EBT Excluding Unusual Items | -75.91 | -86.91 | -113.35 | -142.07 | -83.95 | -103.26 | Upgrade
|
Other Unusual Items | - | - | -49.08 | - | - | - | Upgrade
|
Pretax Income | -75.91 | -86.91 | -162.42 | -142.07 | -83.95 | -103.26 | Upgrade
|
Income Tax Expense | 1.44 | 1.03 | 0.99 | -6.41 | 0.04 | 0.01 | Upgrade
|
Net Income | -77.34 | -87.94 | -163.42 | -135.67 | -83.99 | -103.27 | Upgrade
|
Net Income to Common | -77.34 | -87.94 | -163.42 | -135.67 | -83.99 | -103.27 | Upgrade
|
Shares Outstanding (Basic) | 48 | 48 | 41 | 34 | 30 | 25 | Upgrade
|
Shares Outstanding (Diluted) | 48 | 48 | 41 | 34 | 30 | 25 | Upgrade
|
Shares Change (YoY) | 11.15% | 16.23% | 20.31% | 12.07% | 20.08% | 119.84% | Upgrade
|
EPS (Basic) | -1.61 | -1.85 | -4.00 | -4.01 | -2.77 | -4.09 | Upgrade
|
EPS (Diluted) | -1.61 | -1.85 | -4.00 | -4.02 | -2.77 | -4.09 | Upgrade
|
Free Cash Flow | -7.87 | 9.33 | -71.05 | -120.41 | -132.78 | -89.3 | Upgrade
|
Free Cash Flow Per Share | -0.16 | 0.20 | -1.74 | -3.54 | -4.38 | -3.54 | Upgrade
|
Gross Margin | 77.11% | 75.77% | 74.76% | 83.94% | 90.06% | - | Upgrade
|
Operating Margin | -20.12% | -26.00% | -58.57% | -170.28% | -906.12% | - | Upgrade
|
Profit Margin | -20.39% | -26.10% | -87.68% | -176.05% | -438.86% | - | Upgrade
|
Free Cash Flow Margin | -2.08% | 2.77% | -38.12% | -156.26% | -693.81% | - | Upgrade
|
EBITDA | -52.3 | -63.98 | -98.33 | -127.98 | -172.82 | -103.99 | Upgrade
|
EBITDA Margin | -13.79% | -18.99% | -52.76% | -166.08% | - | - | Upgrade
|
D&A For EBITDA | 24.02 | 23.63 | 10.83 | 3.24 | 0.6 | 0.31 | Upgrade
|
EBIT | -76.32 | -87.61 | -109.15 | -131.22 | -173.41 | -104.3 | Upgrade
|
EBIT Margin | -20.12% | -26.00% | -58.57% | -170.28% | - | - | Upgrade
|
Revenue as Reported | 379.25 | 336.89 | 186.37 | 77.06 | 19.14 | - | Upgrade
|
Advertising Expenses | - | 11.5 | 6.3 | 4 | 9.2 | - | Upgrade
|
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.